Extended-release trazodone in the treatment of major depressive disorder

被引：0
|
作者：
Karamustafalioglu, Oguz [1 ]
Dilbaz, Nesrin [2 ]
Caykoylu, Ali [3 ]
Alkin, Tunc [4 ]
Gonul, Ali Saffet [5 ]
Atmaca, Murad [6 ]
机构：
[1] Adli Tip Kurumu, Istanbul, Turkey
[2] Uskudar Univ, ITBF Psikol Bolumu, Istanbul, Turkey
[3] Ankara Yildirim Beyazit Univ, Psikiyatri & Davranissal Norobilim Uygulama & Ara, Ankara, Turkey
[4] Dokuz Eylul Univ, Tip Fak, Psikiyatri ABD, Izmir, Turkey
[5] Ege Univ, Tip Fak, Psikiyatri ABD, Izmir, Turkey
[6] Firat Univ, Tip Fak, Psikiyatri ABD, Elazig, Turkey
来源：
ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY | 2019年 / 20卷 / 05期
关键词：
major depressive disorder; extended-release trazodone (single dose of TzCOAD per day); immediate-release trazodone (three doses of TzIR per day); PROLONGED-RELEASE; TOLERABILITY; EFFICACY;
D O I：
10.5455/apd.302644467
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
Major depressive disorder is a common psychiatric disorder. The aim of the treatment is to improve daily functions with remissions in symptoms, and antidepressants are the first-line treatments for a major depressive episode (moderate-severe depressive episode). In this paper, the pharmacological properties, clinical efficacy and safety of extended-release trazodone (TzCOAD) are studied. Expert opinion: A single daily dose of TzCOAD may provide similar efficacy and increased tolerability to immediate-release trazodone (TzIR) and other antidepressants.
引用
收藏
页码：453 / 459
页数：7
相关论文
共 50 条
  • [41] Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder
    Seetasith, Arpamas
    Greene, Mallik
    Hartry, Ann
    Burudpakdee, Chakkarin
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 741 - 755
  • [42] Improved sleep impact in patients with Major Depressive Disorder treated with zolpidem tartrate extended-release in combination with escitalopram
    Lasch, K. E.
    Joish, V
    Zhu, Y.
    Rosa, K.
    Crawford, B.
    SLEEP, 2008, 31 : A325 - A325
  • [43] Extended-release venlafaxine in relapse prevention for patients with major depressive disorder (vol 38, pg 249, 2004)
    Simon, JS
    JOURNAL OF PSYCHIATRIC RESEARCH, 2004, 38 (04) : 451 - 451
  • [44] Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder
    Bauer, Michael
    Thase, Michael E.
    Liu, Sherry
    Earley, Willie
    Eriksson, Hans
    JOURNAL OF PSYCHOPHARMACOLOGY, 2015, 29 (05) : 565 - 574
  • [45] Efficacy of adjunct quetiapine extended-release in major depressive disorder: a pooled analysis of SSRI and SNRI patient subgroups
    Bauer, M.
    Demyttenaere, K.
    El-Khalili, N.
    Thase, M.
    Papakostas, G. I.
    Szamosi, J.
    Earley, W.
    Eriksson, H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S441 - S442
  • [46] Quetiapine extended release: a guide to its use as adjunctive treatment in major depressive disorder
    Gillian M. Keating
    Mark Sanford
    Drugs & Therapy Perspectives, 2012, 28 (3) : 7 - 11
  • [47] Efficacy of levomilnacipran extended release in treating major depressive disorder
    Ragguett, Renee-Marie
    Yim, Samantha J.
    Ho, Peter T.
    McIntyre, Roger S.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (18) : 2017 - 2024
  • [48] Early efficacy of trazodone for the treatment of depressive episodes with mixed features in patients with major depressive disorder
    Lo Serro, V.
    Crapanzano, C.
    Goracci, A.
    Bolognesi, S.
    Di Cicco, G.
    Cini, E.
    Carmellini, P.
    Famularo, I.
    Fagiolini, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S212 - S213
  • [49] The efficacy of extended-release carbamazepine therapy for depressive symptoms in bipolar I disorder
    Swann, AC
    BIPOLAR DISORDERS, 2005, 7 : 105 - 105
  • [50] Quetiapine Extended ReleaseAdjunctive Treatment in Major Depressive Disorder
    Mark Sanford
    CNS Drugs, 2011, 25 : 803 - 813
12345